Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 study of DSF100 ( Epoladerm ) for chronic pain associated with osteoarthritis of the knee

Next Previous
Trial Profile

A Phase 1 study of DSF100 ( Epoladerm ) for chronic pain associated with osteoarthritis of the knee

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 17 Nov 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Diclofenac hydroxyethylpyrrolidine (Primary) ; Diclofenac
  • Indications Musculoskeletal pain; Osteoarthritis
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Virpax Pharmaceuticals

Most Recent Events

  • 09 Nov 2022 According to a Virpax Pharmaceuticals media release, MedPharm, from whom Virpax licenses Epoladerm is working on a revised formulation. This work is expected to be completed in the first quarter of 2023, enabling the trial to start towards the end of 2023.
  • 09 Nov 2022 According to a Virpax Pharmaceuticals media release, the company had experienced delays in initiating enrollment for this clinical study that were initially due to a delay in procuring the active pharmaceutical ingredient necessary for the drug product candidate and delays related to supply chain disruptions. Recently, the company discovered a degradant issue after an extensive review of the formulation.
  • 22 Mar 2022 According to a Virpax Pharmaceuticals media release, the company has completed all FDA required pre-clinical studies for Epoladerm.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top